Life Science Partners, a Dutch venture capital firm has invested €4 million in a €11.5 million series A financing round of ActoGeniX, a Belgian bio-pharmaceutical company.
The transaction was led by Life Science Partners and GIMV, a Dutch rival.
Life Sciences Partners also appointed of Martijn Kleijwegt as a non-executive director representing the firm on the supervisory board of ActoGeniX.
With this financing, ActoGeniX will focus on developing therapeutic products based on its TopAct technology, a proprietary delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals.
ActoGeniX products will address a broad range of diseases, such as gastrointestinal diseases, auto-immunity, allergy and metabolic disease.
The company’s lead product for the treatment of Crohn’s disease has already successfully been tested in patients.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: